Search Results - cynthia+berlinicke

4 Results

Sort By:

Novel inhibitors of protein kinase signaling that are neuroprotective and have potential applicability for the treatment of glaucoma, optic nerve disease, and other forms of neurodegeneration - #2

Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop neuroprotective agents that promote the survival of neurons. Through a high content screen of libraries of small molecule compounds,...

Published: 6/27/2024 | Inventor(s): Laszlo Hackler, Dana Ferraris, Cynthia Berlinicke, James Inglese, Tomas Vojkovsky, Joseph Steiner, Barbara Slusher, Zhiyong Yang, Donald Zack

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Eye Disorders, Multiple CNS Indications, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Novel Inhibitors of Protein Kinase Signaling that are Neuroprotective and have Potential Applicability for the Treatment of Glaucoma, Optic Nerve Disease, and other Forms of Neurodegeneration

Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop “neuroprotective” agents that promote the survival of neurons. We have synthesized and tested a number of novel compounds, based...

Published: 6/27/2024 | Inventor(s): Tomas Vojkovsky, Cynthia Berlinicke, William Roush, Thomas Bannister, Zhiyong Yang, Donald Zack

Keywords(s): CNS and Neurological Disorders, Disease Indication, Eye Disorders, Glaucoma, Optic Nerve Diseases, Optic Neuropathy, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology > Glaucoma, Clinical and Disease Specializations > Ophthalmology > Optic Neuropathy, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology

A Neuroprotective Agent with Applicability to Glaucoma, Optic Nerve Diseases, and other Neurodegenerations

C10454: Known Drug found to have applicability in the area of glaucoma, optic nerve diseases, and other neurodegenerationsValue Proposition: Key Features • Provides treatment for glaucoma, other optic nerve diseases, and potentially any disease with neuronal dysfunction or loss. • Exploits an FDA approved drug, which may reduce clinical hurdles and...

Published: 6/27/2024 | Inventor(s): Zhiyong Yang, Cynthia Berlinicke, Harry Quigley, Donald Zack

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Eye Disorders, Glaucoma, Non-novel, Optic Nerve Diseases, Optic Neuropathy, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology > Glaucoma, Clinical and Disease Specializations > Ophthalmology > Optic Neuropathy, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities

A p105-based NF-(kappa) B Super repressor

C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...

Published: 6/27/2024 | Inventor(s): Li Lin

Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities